{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:26:08Z","timestamp":1794072368704,"version":"4.8.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microbiome"],"DOI":"10.1186\/s40168-025-02045-6","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:54:59Z","timestamp":1740725699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy"],"prefix":"10.1186","volume":"13","author":[{"given":"Alba","family":"Rodr\u00edguez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ancos-Pintado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Ortiz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luz","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guevara-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Selma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Frutos-Lis\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.","family":"Tom\u00e1s-Barber\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2045_CR1","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390. https:\/\/doi.org\/10.1056\/NEJMoa070389.","journal-title":"N Engl J Med"},{"key":"2045_CR2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/ijc.28479","volume":"134","author":"CM McShane","year":"2014","unstructured":"McShane CM, Murray LJ, Engels EA, Landgren O, Anderson LA. Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study: infections and multiple myeloma. Int J Cancer. 2014;134:1734\u201340. https:\/\/doi.org\/10.1002\/ijc.28479.","journal-title":"Int J Cancer"},{"key":"2045_CR3","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1182\/blood-2008-07-167569","volume":"112","author":"E Bigot-Corbel","year":"2008","unstructured":"Bigot-Corbel E, Gassin M, Corre I, Le Carrer D, Delaroche O, Hermouet S. Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy. Blood. 2008;112:4357\u20138. https:\/\/doi.org\/10.1182\/blood-2008-07-167569.","journal-title":"Blood"},{"key":"2045_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jvh.12742","volume":"24","author":"Y Li","year":"2017","unstructured":"Li Y, Li Y, Zhang L, Li W. Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies. J Viral Hepat. 2017;24:1151\u20139. https:\/\/doi.org\/10.1111\/jvh.12742.","journal-title":"J Viral Hepat"},{"key":"2045_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.09.002","volume":"27","author":"J Yan","year":"2017","unstructured":"Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol. 2017;27:1\u20136. https:\/\/doi.org\/10.1016\/j.anndiagpath.2016.09.002.","journal-title":"Ann Diagn Pathol"},{"key":"2045_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1056\/NEJM200301093480219","volume":"348","author":"S Hermouet","year":"2003","unstructured":"Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW. Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia. N Engl J Med. 2003;348:178\u20139. https:\/\/doi.org\/10.1056\/NEJM200301093480219.","journal-title":"N Engl J Med"},{"key":"2045_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ab.2012.10.012","volume":"433","author":"D Feron","year":"2013","unstructured":"Feron D, Charlier C, Gourain V, Garderet L, Coste-Burel M, Le Pape P, Weigel P, Jacques Y, Hermouet S, Bigot-Corbel E. Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins. Anal Biochem. 2013;433:202\u20139. https:\/\/doi.org\/10.1016\/j.ab.2012.10.012.","journal-title":"Anal Biochem"},{"key":"2045_CR8","doi-asserted-by":"publisher","first-page":"960829","DOI":"10.3389\/fimmu.2022.960829","volume":"13","author":"M Linares","year":"2022","unstructured":"Linares M, Hermouet S. Editorial: the role of microorganisms in multiple myeloma. Front Immunol. 2022;13:960829. https:\/\/doi.org\/10.3389\/fimmu.2022.960829.","journal-title":"Front Immunol"},{"key":"2045_CR9","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Garc\u00eda A, Mennesson N, Hernandez-Ibarburu G, Morales ML, Garderet L, Bouchereau L, Allain-Maillet S, Piver E, Marb\u00e1n I, Rubio D, et al. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283096.","DOI":"10.3324\/haematol.2023.283096"},{"key":"2045_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121\u201341. https:\/\/doi.org\/10.1016\/j.cell.2014.03.011.","journal-title":"Cell"},{"key":"2045_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"2045_CR12","doi-asserted-by":"publisher","first-page":"8269","DOI":"10.12659\/MSM.919988","volume":"25","author":"B Zhang","year":"2019","unstructured":"Zhang B, Gu J, Liu J, Huang B, Li J. Fecal microbiota taxonomic shifts in Chinese multiple myeloma patients analyzed by quantitative polimerase chain reaction (QPCR) and 16S rRNA high-throughput sequencing. Med Sci Monit. 2019;25:8269\u201380. https:\/\/doi.org\/10.12659\/MSM.919988.","journal-title":"Med Sci Monit"},{"key":"2045_CR13","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","volume":"9","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun. 2018;9:4832. https:\/\/doi.org\/10.1038\/s41467-018-07305-8.","journal-title":"Nat Commun"},{"key":"2045_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","volume":"8","author":"X Jian","year":"2020","unstructured":"Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, et al. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome. 2020;8:74. https:\/\/doi.org\/10.1186\/s40168-020-00854-5.","journal-title":"Microbiome"},{"key":"2045_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1900623","volume":"382","author":"JU Peled","year":"2020","unstructured":"Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020;382:822\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1900623.","journal-title":"N Engl J Med"},{"key":"2045_CR16","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/bloodadvances.2019032276","volume":"3","author":"MJ Pianko","year":"2019","unstructured":"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, et al. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 2019;3:2040\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2019032276.","journal-title":"Blood Adv"},{"key":"2045_CR17","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2019-130643","volume":"134","author":"C Antoine Pepeljugoski","year":"2019","unstructured":"Antoine Pepeljugoski C, Morgan G, Braunstein M. Analysis of intestinal microbiome in multiple myeloma reveals progressive dysbiosis compared to MGUS and healthy individuals. Blood. 2019;134:3076. https:\/\/doi.org\/10.1182\/blood-2019-130643.","journal-title":"Blood"},{"key":"2045_CR18","doi-asserted-by":"publisher","first-page":"e000576","DOI":"10.1136\/jitc-2020-000576","volume":"8","author":"N Ahmed","year":"2020","unstructured":"Ahmed N, Ghannoum M, Gallogly M, de Lima M, Malek E. Influence of gut microbiome on multiple myeloma: friend or foe? J Immunother Cancer. 2020;8:e000576. https:\/\/doi.org\/10.1136\/jitc-2020-000576.","journal-title":"J Immunother Cancer"},{"key":"2045_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/ijms22031026","volume":"22","author":"M Uribe-Herranz","year":"2021","unstructured":"Uribe-Herranz M, Klein-Gonz\u00e1lez N, Rodr\u00edguez-Lobato LG, Juan M, Fern\u00e1ndez de Larrea C. Gut microbiota influence in hematological malignancies: from genesis to cure. Int J Mol Sci. 2021;22:1026. https:\/\/doi.org\/10.3390\/ijms22031026.","journal-title":"Int J Mol Sci"},{"key":"2045_CR20","doi-asserted-by":"publisher","unstructured":"Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, et al. Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets. Clin Cancer Res. 2022:OF1\u2013OF7. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0723.","DOI":"10.1158\/1078-0432.CCR-22-0723"},{"key":"2045_CR21","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Garc\u00eda A, Arroyo A, Garcia-Vicente R, Morales ML, G\u00f3mez-Gordo R, Justo P, Cuellar C, S\u00e1nchez-Pina J, L\u00f3pez N, Alonso R, et al. Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0195.","DOI":"10.1158\/1078-0432.CCR-23-0195"},{"key":"2045_CR22","doi-asserted-by":"publisher","first-page":"647582","DOI":"10.3389\/fnut.2021.647582","volume":"8","author":"SA Al-Harbi","year":"2021","unstructured":"Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI. Urolithins: the gut based polyphenol metabolites of ellagitannins in cancer prevention, a review. Front Nutr. 2021;8:647582. https:\/\/doi.org\/10.3389\/fnut.2021.647582.","journal-title":"Front Nutr"},{"key":"2045_CR23","doi-asserted-by":"publisher","unstructured":"D\u2019Amico D, Andreux PA, Vald\u00e9s P, Singh A, Rinsch C, Auwerx J. Impact of the natural compound urolithin A on health, disease, and aging. Trends Mol Med. 2021:S1471491421001180. https:\/\/doi.org\/10.1016\/j.molmed.2021.04.009.","DOI":"10.1016\/j.molmed.2021.04.009"},{"key":"2045_CR24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1039\/C4FO00092G","volume":"5","author":"MV Selma","year":"2014","unstructured":"Selma MV, Beltr\u00e1n D, Garc\u00eda-Villalba R, Esp\u00edn JC, Tom\u00e1s-Barber\u00e1n FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 2014;5:1779\u201384. https:\/\/doi.org\/10.1039\/C4FO00092G.","journal-title":"Food Funct"},{"key":"2045_CR25","doi-asserted-by":"publisher","unstructured":"Zhang M, Cui S, Mao B, Zhang Q, Zhao J, Zhang H, Tang X, Chen W. Ellagic acid and intestinal microflora metabolite urolithin A: a review on its sources, metabolic distribution, health benefits, and biotransformation. Crit Rev Food Sci Nutr. 2022:1\u201323. https:\/\/doi.org\/10.1080\/10408398.2022.2036693.","DOI":"10.1080\/10408398.2022.2036693"},{"key":"2045_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nm.4132","volume":"22","author":"D Ryu","year":"2016","unstructured":"Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-dit-F\u00e9lix AA, Williams EG, Jha P, Lo Sasso G, Huzard D, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016;22:879\u201388. https:\/\/doi.org\/10.1038\/nm.4132.","journal-title":"Nat Med"},{"key":"2045_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/scitranslmed.abb0319","volume":"13","author":"P Luan","year":"2021","unstructured":"Luan P, D\u2019Amico D, Andreux PA, Laurila P-P, Wohlwend M, Li H, Imamura de Lima T, Place N, Rinsch C, Zanou N, et al. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Sci Transl Med. 2021;13:319. https:\/\/doi.org\/10.1126\/scitranslmed.abb0319.","journal-title":"Sci Transl Med"},{"key":"2045_CR28","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cancers13071662","volume":"13","author":"A Ortiz-Ruiz","year":"2021","unstructured":"Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, Garc\u00eda-Ortiz A, Valeri A, B\u00e1rcena C, Garc\u00eda-Martin RM, Garrido V, Moreno L, et al. Myc-related mitochondrial activity as a novel target for multiple myeloma. Cancers. 2021;13:1662. https:\/\/doi.org\/10.3390\/cancers13071662.","journal-title":"Cancers"},{"key":"2045_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12192-020-01189-8","volume":"26","author":"MS El-Wetidy","year":"2021","unstructured":"El-Wetidy MS, Ahmad R, Rady I, Helal H, Rady MI, Vaali-Mohammed M-A, Al-Khayal K, Traiki TB, Abdulla M-H. Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53\u2013p21 proteins and reactive oxygen species production in colorectal cancer cells. Cell Stress Chaperones. 2021;26:473\u201393. https:\/\/doi.org\/10.1007\/s12192-020-01189-8.","journal-title":"Cell Stress Chaperones"},{"key":"2045_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1535-7163.MCT-18-0464","volume":"18","author":"TM Totiger","year":"2019","unstructured":"Totiger TM, Srinivasan S, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA, Joshi C, Rangappa S, Castellanos J, Vemula PK, et al. Urolithin A, a novel natural compound to target PI3K\/AKT\/mTOR pathway in pancreatic cancer. Mol Cancer Ther. 2019;18:301\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0464.","journal-title":"Mol Cancer Ther"},{"key":"2045_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/mnfr.200800150","volume":"53","author":"A Gonz\u00e1lez-Sarr\u00edas","year":"2009","unstructured":"Gonz\u00e1lez-Sarr\u00edas A, Esp\u00edn J-C, Tom\u00e1s-Barber\u00e1n FA, Garc\u00eda-Conesa M-T. Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. Mol Nutr Food Res. 2009;53:686\u201398. https:\/\/doi.org\/10.1002\/mnfr.200800150.","journal-title":"Mol Nutr Food Res"},{"key":"2045_CR32","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852\u20137. https:\/\/doi.org\/10.1038\/s41587-019-0209-9.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2045_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581\u20133. https:\/\/doi.org\/10.1038\/nmeth.3869.","journal-title":"Nat Methods"},{"key":"2045_CR34","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gks1219","volume":"41","author":"C Quast","year":"2013","unstructured":"Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Gl\u00f6ckner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41:D590\u20136. https:\/\/doi.org\/10.1093\/nar\/gks1219.","journal-title":"Nucleic Acids Res"},{"key":"2045_CR35","doi-asserted-by":"publisher","first-page":"e2584","DOI":"10.7717\/peerj.2584","volume":"4","author":"T Rognes","year":"2016","unstructured":"Rognes T, Flouri T, Nichols B, Quince C, Mah\u00e9 F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584. https:\/\/doi.org\/10.7717\/peerj.2584.","journal-title":"PeerJ"},{"issue":"6","key":"2045_CR36","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","volume":"12","author":"N Segata","year":"2011","unstructured":"Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. https:\/\/doi.org\/10.1186\/gb-2011-12-6-r60.","journal-title":"Genome Biol"},{"key":"2045_CR37","doi-asserted-by":"publisher","first-page":"11099","DOI":"10.1021\/acs.jafc.9b04435","volume":"67","author":"R Garc\u00eda-Villalba","year":"2019","unstructured":"Garc\u00eda-Villalba R, Selma MV, Esp\u00edn JC, Tom\u00e1s-Barber\u00e1n FA. Identification of novel urolithin metabolites in human feces and urine after the intake of a pomegranate extract. J Agric Food Chem. 2019;67:11099\u2013107. https:\/\/doi.org\/10.1021\/acs.jafc.9b04435.","journal-title":"J Agric Food Chem"},{"key":"2045_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.chroma.2015.08.044","volume":"1428","author":"R Garc\u00eda-Villalba","year":"2016","unstructured":"Garc\u00eda-Villalba R, Esp\u00edn JC, Tom\u00e1s-Barber\u00e1n FA. Chromatographic and spectroscopic characterization of urolithins for their determination in biological samples after the intake of foods containing ellagitannins and ellagic acid. J Chromatogr A. 2016;1428:162\u201375. https:\/\/doi.org\/10.1016\/j.chroma.2015.08.044.","journal-title":"J Chromatogr A"},{"key":"2045_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947.","journal-title":"Cancer Res"},{"key":"2045_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods. 2001;25:402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"},{"key":"2045_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/antiox8110508","volume":"8","author":"A Rodr\u00edguez-Garc\u00eda","year":"2019","unstructured":"Rodr\u00edguez-Garc\u00eda A, Morales ML, Garrido-Garc\u00eda V, Garc\u00eda-Baquero I, Leivas A, Carre\u00f1o-Tarragona G, S\u00e1nchez R, Arenas A, Cedena T, Ayala RM, et al. Protein carbonylation in patients with myelodysplastic syndrome: an opportunity for deferasirox therapy. Antioxidants. 2019;8:508. https:\/\/doi.org\/10.3390\/antiox8110508.","journal-title":"Antioxidants"},{"key":"2045_CR42","unstructured":"RStudio Team. RStudio: integrated development for R. Boston: RStudio, PBC. 2020. http:\/\/www.rstudio.com\/."},{"key":"2045_CR43","doi-asserted-by":"publisher","first-page":"1800958","DOI":"10.1002\/mnfr.201800958","volume":"63","author":"M Romo-Vaquero","year":"2019","unstructured":"Romo-Vaquero M, Cort\u00e9s-Mart\u00edn A, Loria-Kohen V, Ram\u00edrez-de-Molina A, Garc\u00eda-Mantrana I, Collado MC, Esp\u00edn JC, Selma MV. Deciphering the human gut microbiome of urolithin metabotypes: association with enterotypes and potential cardiometabolic health implications. Mol Nutr Food Res. 2019;63:1800958. https:\/\/doi.org\/10.1002\/mnfr.201800958.","journal-title":"Mol Nutr Food Res"},{"key":"2045_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nmni.2016.12.016","volume":"16","author":"M Bilen","year":"2017","unstructured":"Bilen M, Cadoret F, Dubourg G, Daoud Z, Fournier PE, Raoult D. \u2018Raoultibacter timonensis\u2019 gen. nov., sp. nov. , a new bacterium isolated from the human gut of a Pygmy woman. New Microbes New Infect. 2017;16:45\u20136. https:\/\/doi.org\/10.1016\/j.nmni.2016.12.016.","journal-title":"New Microbes New Infect"},{"key":"2045_CR45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2019-320438","volume":"69","author":"V Meslier","year":"2020","unstructured":"Meslier V, Laiola M, Roager HM, De Filippis F, Roume H, Quinquis B, Giacco R, Mennella I, Ferracane R, Pons N, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut. 2020;69:1258\u201368. https:\/\/doi.org\/10.1136\/gutjnl-2019-320438.","journal-title":"Gut"},{"key":"2045_CR46","doi-asserted-by":"publisher","first-page":"113470","DOI":"10.1016\/j.foodres.2023.113470","volume":"173","author":"CE Iglesias-Aguirre","year":"2023","unstructured":"Iglesias-Aguirre CE, Romo-Vaquero M, Victoria Selma M, Carlos EJ. Unveiling metabotype clustering in resveratrol, daidzein, and ellagic acid metabolism: prevalence, associated gut microbiomes, and their distinctive microbial networks. Food Res Int Ott Ont. 2023;173:113470. https:\/\/doi.org\/10.1016\/j.foodres.2023.113470.","journal-title":"Food Res Int Ott Ont"},{"key":"2045_CR47","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/nu11102483","volume":"11","author":"I Garc\u00eda-Mantrana","year":"2019","unstructured":"Garc\u00eda-Mantrana I, Calatayud M, Romo-Vaquero M, Esp\u00edn JC, Selma MV, Collado MC. Urolithin metabotypes can determine the modulation of gut microbiota in healthy individuals by tracking walnuts consumption over three days. Nutrients. 2019;11:2483. https:\/\/doi.org\/10.3390\/nu11102483.","journal-title":"Nutrients"},{"key":"2045_CR48","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107 KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2019;8. https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2018.00665. Accessed 15 Sept 2022.","DOI":"10.3389\/fonc.2018.00665"},{"key":"2045_CR49","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1039\/c8fo00956b","volume":"9","author":"A Cort\u00e9s-Mart\u00edn","year":"2018","unstructured":"Cort\u00e9s-Mart\u00edn A, Garc\u00eda-Villalba R, Gonz\u00e1lez-Sarr\u00edas A, Romo-Vaquero M, Loria-Kohen V, Ram\u00edrez-de-Molina A, Tom\u00e1s-Barber\u00e1n FA, Selma MV, Esp\u00edn JC. The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging. Food Funct. 2018;9:4100\u20136. https:\/\/doi.org\/10.1039\/c8fo00956b.","journal-title":"Food Funct"},{"key":"2045_CR50","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1021\/jf5024615","volume":"62","author":"FA Tom\u00e1s-Barber\u00e1n","year":"2014","unstructured":"Tom\u00e1s-Barber\u00e1n FA, Garc\u00eda-Villalba R, Gonz\u00e1lez-Sarr\u00edas A, Selma MV, Esp\u00edn JC. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem. 2014;62:6535\u20138. https:\/\/doi.org\/10.1021\/jf5024615.","journal-title":"J Agric Food Chem"},{"key":"2045_CR51","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1039\/D2FO00552B","volume":"13","author":"M Romo-Vaquero","year":"2022","unstructured":"Romo-Vaquero M, Fern\u00e1ndez-Villalba E, Gil-Martinez A-L, Cuenca-Bermejo L, Carlos Esp\u00edn J, Trinidad Herrero M, Victoria SM. Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson\u2019s patients. Food Funct. 2022;13:6306\u201316. https:\/\/doi.org\/10.1039\/D2FO00552B.","journal-title":"Food Funct"},{"key":"2045_CR52","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1021\/acs.jafc.2c08889","volume":"71","author":"CE Iglesias-Aguirre","year":"2023","unstructured":"Iglesias-Aguirre CE, Garc\u00eda-Villalba R, Beltr\u00e1n D, Frutos-Lis\u00f3n MD, Esp\u00edn JC, Tom\u00e1s-Barber\u00e1n FA, Selma MV. Gut bacteria involved in ellagic acid metabolism to yield human urolithin metabotypes revealed. J Agric Food Chem. 2023;71:4029\u201335. https:\/\/doi.org\/10.1021\/acs.jafc.2c08889.","journal-title":"J Agric Food Chem"},{"key":"2045_CR53","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1039\/d2fo03957e","volume":"14","author":"CE Iglesias-Aguirre","year":"2023","unstructured":"Iglesias-Aguirre CE, Gonz\u00e1lez-Sarr\u00edas A, Cort\u00e9s-Mart\u00edn A, Romo-Vaquero M, Osuna-Galisteo L, Cer\u00f3n JJ, Esp\u00edn JC, Selma MV. In vivo administration of gut bacterial consortia replicates urolithin metabotypes A and B in a non-urolithin-producing rat model. Food Funct. 2023;14:2657\u201367. https:\/\/doi.org\/10.1039\/d2fo03957e.","journal-title":"Food Funct"},{"key":"2045_CR54","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.mam.2022.101109","volume":"89","author":"R Garc\u00eda-Villalba","year":"2022","unstructured":"Garc\u00eda-Villalba R, Tom\u00e1s-Barber\u00e1n FA, Iglesias-Aguirre CE, Gim\u00e9nez-Bastida JA, Gonz\u00e1lez-Sarr\u00edas A, Selma MV, Esp\u00edn JC. Ellagitannins, urolithins, and neuroprotection: human evidence and the possible link to the gut microbiota. Mol Aspects Med. 2022;89:101109. https:\/\/doi.org\/10.1016\/j.mam.2022.101109.","journal-title":"Mol Aspects Med"},{"key":"2045_CR55","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Sarr\u00edas A, Garc\u00eda-Villalba R, Romo-Vaquero M, Alasalvar C, \u00d6rem A, Zafrilla P, Tom\u00e1s-Barber\u00e1n FA, Selma MV, Esp\u00edn JC. Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: a randomized clinical trial. Mol Nutr Food Res. 2017;61. https:\/\/doi.org\/10.1002\/mnfr.201600830.","DOI":"10.1002\/mnfr.201600830"},{"key":"2045_CR56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/carcin\/bgy158","volume":"40","author":"E Norden","year":"2019","unstructured":"Norden E, Heiss EH. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53\/TIGAR axis in colon cancer cells. Carcinogenesis. 2019;40:93\u2013101. https:\/\/doi.org\/10.1093\/carcin\/bgy158.","journal-title":"Carcinogenesis"},{"key":"2045_CR57","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/mc.22848","volume":"57","author":"NR Dahiya","year":"2018","unstructured":"Dahiya NR, Chandrasekaran B, Kolluru V, Ankem M, Damodaran C, Vadhanam MV. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer. Mol Carcinog. 2018;57:1332\u201341. https:\/\/doi.org\/10.1002\/mc.22848.","journal-title":"Mol Carcinog"},{"key":"2045_CR58","doi-asserted-by":"publisher","first-page":"90501","DOI":"10.18632\/oncotarget.18765","volume":"8","author":"A Maes","year":"2017","unstructured":"Maes A, Menu E, Veirman KD, Maes K, Vand erkerken K, De Bruyne E. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget. 2017;8:90501\u201320. https:\/\/doi.org\/10.18632\/oncotarget.18765.","journal-title":"Oncotarget"},{"key":"2045_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00432-007-0278-x","volume":"134","author":"L Gaul","year":"2008","unstructured":"Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 2008;134:245\u201353. https:\/\/doi.org\/10.1007\/s00432-007-0278-x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2045_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3892\/ijo.2012.1448","volume":"41","author":"YS Hong","year":"2012","unstructured":"Hong YS, Hong S-W, Kim S-M, Jin D-H, Shin J-S, Yoon DH, Kim K-P, Lee J-L, Heo DS, Lee JS, et al. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol. 2012;41:76\u201382. https:\/\/doi.org\/10.3892\/ijo.2012.1448.","journal-title":"Int J Oncol"},{"key":"2045_CR61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10637-017-0483-7","volume":"35","author":"J Liberal","year":"2017","unstructured":"Liberal J, Carmo A, Gomes C, Cruz MT, Batista MT. Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells. Invest New Drugs. 2017;35:671\u201381. https:\/\/doi.org\/10.1007\/s10637-017-0483-7.","journal-title":"Invest New Drugs"},{"key":"2045_CR62","doi-asserted-by":"publisher","first-page":"e247504","DOI":"10.1155\/2013\/247504","volume":"2013","author":"R Vicinanza","year":"2013","unstructured":"Vicinanza R, Zhang Y, Henning SM, Heber D. Pomegranate juice metabolites, ellagic acid and urolithin A, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid Based Complement Alternat Med. 2013;2013:e247504. https:\/\/doi.org\/10.1155\/2013\/247504.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2045_CR63","first-page":"3658","volume":"8","author":"WS Dalton","year":"2002","unstructured":"Dalton WS. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8:3658\u201368.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2045_CR64","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.fct.2013.06.025","volume":"59","author":"Z Qiu","year":"2013","unstructured":"Qiu Z, Zhou B, Jin L, Yu H, Liu L, Liu Y, Qin C, Xie S, Zhu F. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2013;59:428\u201337. https:\/\/doi.org\/10.1016\/j.fct.2013.06.025.","journal-title":"Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc"},{"key":"2045_CR65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.tiv.2015.04.008","volume":"29","author":"Y Wang","year":"2015","unstructured":"Wang Y, Qiu Z, Zhou B, Liu C, Ruan J, Yan Q, Liao J, Zhu F. In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol Vitro Int J Publ Assoc BIBRA. 2015;29:1107\u201315. https:\/\/doi.org\/10.1016\/j.tiv.2015.04.008.","journal-title":"Toxicol Vitro Int J Publ Assoc BIBRA"},{"key":"2045_CR66","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","volume":"105","author":"BC Lipchick","year":"2016","unstructured":"Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016;105:210\u20135. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.029.","journal-title":"Pharmacol Res"},{"key":"2045_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","volume":"417","author":"MP Murphy","year":"2009","unstructured":"Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1\u201313. https:\/\/doi.org\/10.1042\/BJ20081386.","journal-title":"Biochem J"},{"issue":"5","key":"2045_CR68","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.7150\/ijbs.69116","volume":"18","author":"Z Gao","year":"2022","unstructured":"Gao Z, Yi W, Tang J, Sun Y, Huang J, Lan T, Dai X, Xu S, Jin ZG, Wu X. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. Int J Biol Sci. 2022;18(5):2146\u201362. https:\/\/doi.org\/10.7150\/ijbs.69116.","journal-title":"Int J Biol Sci"},{"key":"2045_CR69","doi-asserted-by":"publisher","first-page":"F1255","DOI":"10.1152\/ajprenal.00346.2019","volume":"317","author":"D Zou","year":"2019","unstructured":"Zou D, Ganugula R, Arora M, Nabity MB, Sheikh-Hamad D, Kumar MNVR. Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI. Am J Physiol Renal Physiol. 2019;317:F1255\u201364. https:\/\/doi.org\/10.1152\/ajprenal.00346.2019.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2045_CR70","doi-asserted-by":"crossref","unstructured":"Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Front Oncol. 2021;11. https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2021.740796. Accessed 29 June 2022.","DOI":"10.3389\/fonc.2021.740796"},{"key":"2045_CR71","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1182\/blood-2004-02-0547","volume":"104","author":"D Chauhan","year":"2004","unstructured":"Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC. Targeting mitochondria to overcome conventional and bortezomib\/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004;104:2458\u201366. https:\/\/doi.org\/10.1182\/blood-2004-02-0547.","journal-title":"Blood"},{"key":"2045_CR72","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft HS, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30:2198\u2013207. https:\/\/doi.org\/10.1038\/leu.2016.102.","journal-title":"Leukemia"},{"key":"2045_CR73","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/onc.2014.133","volume":"34","author":"N-N Kreis","year":"2015","unstructured":"Kreis N-N, Louwen F, Yuan J. Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene. 2015;34:1758\u201367. https:\/\/doi.org\/10.1038\/onc.2014.133.","journal-title":"Oncogene"},{"key":"2045_CR74","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","volume":"414","author":"J Hu","year":"2018","unstructured":"Hu J, Hu W-X. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018;414:214\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.020.","journal-title":"Cancer Lett"},{"key":"2045_CR75","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.bjc.6601741","volume":"90","author":"JA van der Hage","year":"2004","unstructured":"van der Hage JA, van den Broek LJCM, Legrand C, Clahsen PC, Bosch CJA, Robanus-Maandag EC, van de Velde CJH, van de Vijver MJ. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer. 2004;90:1543\u201350. https:\/\/doi.org\/10.1038\/sj.bjc.6601741.","journal-title":"Br J Cancer"},{"key":"2045_CR76","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.canlet.2007.01.026","volume":"253","author":"G Hou","year":"2007","unstructured":"Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR\/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236\u201348. https:\/\/doi.org\/10.1016\/j.canlet.2007.01.026.","journal-title":"Cancer Lett"},{"key":"2045_CR77","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/mc.20402","volume":"47","author":"LS Faried","year":"2008","unstructured":"Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy. Mol Carcinog. 2008;47:446\u201357. https:\/\/doi.org\/10.1002\/mc.20402.","journal-title":"Mol Carcinog"},{"key":"2045_CR78","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.14529","volume":"177","author":"T Calimeri","year":"2017","unstructured":"Calimeri T, Ferreri AJM. m-TOR inhibitors and their potential role in haematological malignancies. Br J Haematol. 2017;177:684\u2013702. https:\/\/doi.org\/10.1111\/bjh.14529.","journal-title":"Br J Haematol"},{"key":"2045_CR79","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1039\/c5fo00120j","volume":"6","author":"A Gonz\u00e1lez-Sarr\u00edas","year":"2015","unstructured":"Gonz\u00e1lez-Sarr\u00edas A, Tom\u00e9-Carneiro J, Bellesia A, Tom\u00e1s Barber\u00e1n FA, Esp\u00edn JC. The ellagic acid-derived gut microbiota metabolite urolithin A potentiates the anticancer effect of 5-fluorouracil chemotherapy in human colon cancer cells. Food Funct. 2015;6:1460\u20139. https:\/\/doi.org\/10.1039\/c5fo00120j.","journal-title":"Food Funct"},{"issue":"12","key":"2045_CR80","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.7150\/thno.70754","volume":"12","author":"S Ghosh","year":"2022","unstructured":"Ghosh S, Singh R, Vanwinkle ZM, Guo H, Vemula PK, Goel A, Haribabu B, Jala VR. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis. Theranostics. 2022;12(12):5574\u201395. https:\/\/doi.org\/10.7150\/thno.70754.","journal-title":"Theranostics"},{"key":"2045_CR81","doi-asserted-by":"publisher","first-page":"101846","DOI":"10.1016\/j.tice.2022.101846","volume":"77","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Iranshahy M, Gholamhosseinian H, Matin MM, Rassouli FB. Urolithins increased anticancer effects of chemical drugs, ionizing radiation and hyperthermia on human esophageal carcinoma cells in vitro. Tissue Cell. 2022;77:101846. https:\/\/doi.org\/10.1016\/j.tice.2022.101846.","journal-title":"Tissue Cell"},{"issue":"7","key":"2045_CR82","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1158\/2767-9764.CRC-22-0329","volume":"3","author":"S Mehra","year":"2023","unstructured":"Mehra S, Garrido VT, Dosch AR, Lamichhane P, Srinivasan S, Singh SP, Zhou Z, De Castro SI, Joshi C, Ban Y, Datta J, Gilboa E, Merchant NB, Nagathihalli NS. Remodeling of stromal immune microenvironment by urolithin A improves survival with immune checkpoint blockade in pancreatic cancer. Cancer Res Commun. 2023;3(7):1224\u201336. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0329.","journal-title":"Cancer Res Commun"},{"issue":"2","key":"2045_CR83","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ddr.22021","volume":"84","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Jiang L, Su P, Yu T, Ma Z, Liu Y, Yu J. Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K\/Akt\/mTOR pathway. Drug Dev Res. 2023;84(2):172\u201384. https:\/\/doi.org\/10.1002\/ddr.22021.","journal-title":"Drug Dev Res"}],"container-title":["Microbiome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-025-02045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40168-025-02045-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-025-02045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T20:12:47Z","timestamp":1741032767000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbiomejournal.biomedcentral.com\/articles\/10.1186\/s40168-025-02045-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2045"],"URL":"https:\/\/doi.org\/10.1186\/s40168-025-02045-6","relation":{},"ISSN":["2049-2618"],"issn-type":[{"value":"2049-2618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hospital 12 de Octubre Ethical Committee (21\/580), and all patients and donors provided written informed consent following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}